* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Multistate Study of Etiology in Newborn Hearing Screening
Survey
Document related concepts
Transcript
A Multistate Study of Etiology in Infants Identified through Universal Newborn Hearing Screening Karin M. Dent, MS, CGC John C. Carey, MD, MPH University of Utah Division of Medical Genetics Department of Pediatrics Congenital Hearing Loss Birth Prevalence: –1 in 300 - 1 in 500 births –includes mild to profound, unilateral and bilateral CHL http://www.iurc.montp.in serm.fr/cric/audition/engli sh/start2.htm Congenital Hearing Loss Rate per 1,000 of Permanent Congenital Hearing Loss in Published Reports of UNHS Programs Prevalence per 103 Location of Program Cohort Size New Jersey, 1997 15,749 3.30 New York, 2000 27, 938 1.96 Colorado, 1998 41,976 2.56 Texas, 1998 54,228 2.15 Hawaii, 1997 9,605 4.15 Estimate = 2- 4 / 1000 I ≈ 1/500 Environmental ~50% Genetic ~50% Syndromic ~30% Branchiootorenal (BOR) CHARGE Syndrome aminoglycosides infections (bacterial or viral) trauma Nonsyndromic ~70% Mitochondrial <1% Autosomal Dominant 20% X-linked ~1% Autosomal Recessive 80% Modified from www.ACMG.net Genetics of Hearing Loss Nonsyndromic Human Hearing Loss Genes* DFNA - Autosomal Dominant – 54 Loci Mapped DFNB - Autosomal Recessive – DFNB1 = GJB2 – 51 Loci Mapped DFN - X-Linked – 7 Loci Mapped Syndromic Hearing Loss Genes 30 single genes known *50% have been identified Hereditary Hearing Loss web page: www.uia.ac.be/dnalab/hhh Genetic Causes of Hearing Loss: Contribution of Cx26 Genetic ~50% Syndromic ~30% Nonsyndromic ~70% Mt <1% Dominant 20% Recessive 80% X-linked ~1% DFNB1 = GJB2 (Connexin 26) – 50% of DFNB - mutations of GJB2 or Connexin 26 ~15% of congenital hearing loss – Cx26 mutations GJB2 / Connexin 26 gene Mechanism – Expressed in the cochlea – Membrane protein forming intracellular channels = Gap Junction protein A / B – Allows recirculation of ions (K+) Nature Genetics, February 2001. Connexin 26 / GJB2 >80 mutations identified 35 del G (formerly del 30) – Carrier freq ≈ 3.5% Caucasians ← GJB2 167 del T – Carrier freq ≈ 4% Ashkenazi Jewish 235 del C – Seen in Asian populations *M34T – Carrier freq ≈ 2-3% Caucasians – Hypothesized as recessive allele Chromosome 13 Kenneson et al., Genet Med, 2002 Study Development Universal Newborn Hearing Screening + Advances in Genetics of Hearing Loss = Prospective study of etiology of congenital hearing loss • Utah, Hawaii, Rhode Island, and the Centers for Disease Control and Prevention Study Objectives To determine the etiology of congenital hearing loss based on children identified through a statewide newborn hearing screening (EHDI) program – To evaluate all children with permanent hearing loss, unilateral or bilateral, of any degree, from a genetic perspective – To determine the frequency of GJB2 and mitochondrial mutations in this population Study Objectives cont… To establish a model infrastructure linking genetic services to statewide newborn hearing screening Hypothesis The majority of infants identified through the newborn hearing screening program will have hearing loss due to various genetic causes including known syndromes and mutations in the GJB2 gene. STUDY DESIGN and FLOW Identified Case Fails screens, enters database Decline to participate Send letter inviting participation in study Genetic Evaluation: Determination of syndrome, pedigree analysis Acquired cause (e.g. CMV) No evidence of syndrome Syndromic (e.g. Waardenburg, CHARGE, etc.) Offer GJB2, mitochondrial testing Nonsyndromic hearing loss Autosomal dominant or Autosomal recessive inheritance X-linked or maternal inheritance Sporadic Offer GJB2 and mitochondrial testing POSITIVE NEGATIVE LVA GJB2 het GJB6 testing Summarize and classify case Offer additional genetic counseling and family member referrals Refer for ophthalmology, EKG (?), etc., through PCP Pendred studies Results 93 Probands (primarily Caucasian / N. European, Hispanic) 20 cases from RI 73 cases from UT – 19 syndromic cases – 1 cases acquired hearing loss CMV induced – 73 cases non-syndromic Results cont… Syndromic cases (19) - Williams syndrome Wolf-Hirschhorn (4p-) CHARGE syndrome 18q deletion syndrome Kabuki syndrome 22q deletion syndrome 10p trisomy syndrome Wildervank - Trisomy 21 Waardenburg x 2 Oculoauriculovertebral VATER Branchiootorenal (BOR) Pendred MCA x 4 Results cont… Nonsyndromic Cases (73) – 8 cases Conductive isolated microtia, meatal atresia – 65 cases Sensorineural 53 Bilateral 12 Unilateral 13 Familial 52 Sporadic • 1 adopted DNA Testing Results of 53 Bilateral Non-syndromic SNHL: GJB2 Results (12) 35 del G / 35 del G homozygote (3) L 90 P / 35 del G cmpd heterozygote 35 del G / 358 del GAG cmpd heterozygote 35 del G heterozygote (3) L 90 P heterozygote S 193 N heterozygote M 34 T heterozygote (2) DNA Testing Results GJB6 Results no mutations found (RI, n = 20) Mitochondrial DNA Results no mutations found Summary 93 probands – 73 nonsyndromic 65 sensorineural hearing loss – 53 bilateral, sensorineural hearing loss 12 / 53 (23%) have GJB2 variant 5 / 53 (9.4%) 35 del G homozygotes or compound heterozygotes Risk Factors for Hearing Loss Prematurity (<37 wks gestation), jaundice, aminoglycoside exposure, external ear defects, family history of hearing loss Risk Factors Utah: Rhode Island: 4 patients with prematurity (1 of 4 w/ aminoglycoside X) 1 pt aminoglycoside exp 8 pts microtia 11 familial pts TOTAL = 24 (full term pgcy) (of 73 probands) 3 patients with prematurity and aminoglycoside exp 2 familial pts Others with jaundice, aminoglycoside exposure, and non-isolated microtia TOTAL > 5 (of 20 probands) Conclusions Frequency of GJB2 mutations in this population is consistent with reported estimates Identification of the etiology of hearing loss allows for accurate genetic counseling in terms of recurrence risk, natural history, and anticipatory guidance. Conclusions Incorporation of genetic services into newborn screening programs for hearing loss is beneficial for families. Majority of newborns identified through universal screening had no clinical risk factors for hearing loss. Future Directions Ascertainment (All) – pt evaluations in outreach clinics – website – parent brochure – Spanish literature DNA Testing (Utah and Hawaii) – Connexin 30 testing – Pendrin testing Contributors - Hawaii Patricia Heu, MD Principal Investigator Sylvia Au, MS, CGC State Genetics Coordinator Genetic Counselors Allison Taylor, MS Lianne Hasagawa, MS Kirsty McWalter, MS Contributors – Rhode Island Betty Vohr, MD Women & Infant’s Hospital Julie Jodoin, MEd, MA Women & Infant’s Hospital Jyllian Anterni, BS Women & Infant’s Hospital Jeffrey Milunsky, MD Boston University Dianne Abuelo, MD Rhode Island Hospital Kristilyn Zonno, MS Rhode Island Hospital Contributors - Utah University of Utah Janice C. Palumbos, MS, CGC Bronte Clifford, BS Rong Mao, PhD Utah State University Karl White, PhD Utah Dept. of Health Richard Harward, MS Contributors Centers for Disease Control and Prevention John Eichwald, MA Aileen Kenneson, PhD Krista Biernath, MD "The information provided in this presentation was supported by Cooperative Agreement Number 01048 from the Centers for Disease Control and Prevention (CDC). The contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC."